FDA Approves Pediatric Use of Protalix Drug

Following the announcement of the most recent FDA approval at the end of last week, shares of Protalix rose by a combined 7.9%.

comments Print
Protalix Biotherapeutics has received expanded permission from the U.S. Food and Drug Administration to market its medication for the treatment of Gaucher’s disease, so that it can now be administered not only...